Form 4: Terns Pharmaceuticals CEO Amy Burroughs Boosts Stake with Significant Stock Purchase

Terns Pharmaceuticals, Inc. CEO and Director Amy L. Burroughs has acquired 23,314 shares of common stock, increasing her direct beneficial ownership in the company.

Summary

• Amy L. Burroughs, Chief Executive Officer and Director of Terns Pharmaceuticals, Inc. (TERN), reported a purchase of common stock.
• On June 25, 2025, Ms. Burroughs acquired 23,314 shares of TERN common stock.
• The shares were purchased at a price of $3.8702 per share.
• Following this transaction, Ms. Burroughs directly beneficially owns a total of 47,083 shares of Terns Pharmaceuticals, Inc. common stock.
• The total beneficial ownership includes 4,160 shares acquired by Ms. Burroughs under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a significant insider purchase by the CEO, indicating confidence in the company's prospects.

Positives

• The Chief Executive Officer and Director, Amy L. Burroughs, purchasing shares indicates confidence in the company's future prospects and valuation.
• Insider buying can be a positive signal to the market, suggesting that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth.

Future Outlook

NA

Industry Context

Insider purchases, particularly by high-ranking executives like a CEO, are often interpreted by investors as a strong signal of management's belief in the company's future performance, potentially indicating an expectation of positive developments or an undervalued stock price relative to industry peers.

Related Party Transactions

• The reported transaction is a direct purchase of common stock by Amy L. Burroughs, the Chief Executive Officer and a Director of Terns Pharmaceuticals, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive indicator of future stock performance and management alignment with shareholder interests.
• Employees may perceive this as a sign of stability and confidence from leadership.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, SEC Form 4, Insider Trading, Stock Purchase, CEO, Director, Beneficial Ownership, Equity Acquisition